Today Sep 22, 2021
Event Image
Back to Events

Abstracts from ASCO: Chronic Lymphocytic Leukemia (CLL)

Wednesday Sep 01, 2021
Event Time 12:15 - 12:45 PM ET
Registration Closed
Event Faculty

Jeff Sharman, MD

Medical Director of Hematology
US Oncology
Eugene, OR
Event Faculty

John Pagel, MD, PhD

Chief of Hematologic Malignancies
Director of Stem Cell Transplant
Swedish Cancer Institute
Seattle, WA

Selecting the optimal treatment for patients with chronic lymphocytic leukemia (CLL) has depended, at least partly, on whether less-favorable genetic aberrations are present. Recent results from several clinical trials of new therapeutic options targeting Burton tyrosine kinase, B-cell leukemia/lymphoma 2, and phosphatidylinositol 4, 5-bisphosphate 3-kinase catalytic subunit delta has shown better outcomes, more favorable progression-free survival rates, and potentially improved tolerability for patients with and without high-risk genetic aberrations. Data from ASCO 2021 has added to our knowledge of these therapies for CLL and will be discussed in this engaging webinar.

Learning Objectives:
*Review the results of recently approved and novel agents under investigation for the treatment of CLL
*Integrate new data into the development of treatment plans for CLL

Event Sponsors

The content for this program has been independently developed by Clinical Care Solutions.